Focetria

Manufactured by Novartis

Sourced in Italy

Focetria is a lab equipment product developed by Novartis. It is designed for performing various laboratory tasks, but a detailed description of its core function cannot be provided while maintaining an unbiased and factual approach without extrapolation.

Automatically generated - may contain errors

Lab products found in correlation

Pandemrix, by GlaxoSmithKline (1 mentions)

2 protocols using focetria

Influenza Vaccine Composition and Dosage Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients from 2009 to 2010 season received the 2009 (H1N1)pdm monovalent MF59-adjuvanted vaccine containing the strain: A/California/7/2009-H1N1 (Focetria, Novartis, Siena, Italy). Patients from 2010 to 2011 and 2011 to 2012 seasons received the trivalent non-adjuvanted inactivated vaccine (Gripavac, Sanofi-Pasteur MSD, Madrid, Spain) containing the strains: A/California/7/2009-H1N1, A/Perth/16/2009-H3N2, and B/Brisbane/60/2008. Patients from 2012 to 2013 season were randomly assigned to received one or two doses of the trivalent non-adjuvanted inactivated vaccine (Mutagrip, Sanofi-Pasteur MSD) with the strains: A/California/7/2009-H1N1, A/Victoria/361/2011-H3N2, and B/Wisconsin/1/2010.

Cordero E., Bulnes-Ramos A., Aguilar-Guisado M., González Escribano F., Olivas I., Torre-Cisneros J., Gavaldá J., Aydillo T., Moreno A., Montejo M., Fariñas M.C., Carratalá J., Muñoz P., Blanes M., Fortún J., Suárez-Benjumea A., López-Medrano F., Roca C., Lara R, & Pérez-Romero P. (2020). Effect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipients. Frontiers in Immunology, 11, 1917.

+ Open protocol

+ Expand

Pandemic H1N1 Vaccine Deployment in Spain

Check if the same lab product or an alternative is used in the 5 most similar protocols

The vaccine included the A/California/07/2009 (H1N1) virus strain. The vaccine brands were Focetria® (Novartis), adjuvanted with MF59, recommended to children and the elderly, Pandemrix® (Glaxo SmithKline), adjuvanted with ASO3, recommended for adults, and Panenza® (Sanofi Pasteur), unadjuvanted, recommended for pregnancy. Actual exposure involved administration of 970,468 doses in the second half of November 2009, 641,829 in December 2009, 114,220 in January 2010, coming to an end in late February 2010, making a total of 1.7 million doses, less than 5 % of which were administered to persons under 18 years of age. In all, 12 % of health care workers, 9 % of workers in essential public services, 15 % of people from 18 to 60 years old with chronic conditions, and 28 % of people 60 years old and over received the vaccine (Division of Vaccination Programmes, Spain’s Ministry of Health, Social Services, and Equality, unpublished report).

Alcalde-Cabero E., Almazán-Isla J., García López F.J., Ara-Callizo J.R., Avellanal F., Casasnovas C., Cemillán C., Cuadrado J.I., Duarte J., Fernández-Pérez M.D., Fernández Ó., Merino J.A., Montero R.G., Montero D., Pardo J., Rodríguez-Rivera F.J., Ruiz-Tovar M, & de Pedro-Cuesta J. (2016). Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. BMC Neurology, 16, 75.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!